AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE-TN Trial for Patients with Previously Untreated Chronic Lymphocytic Leukemia

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE-TN Trial for Patients with Previously Untreated Chronic Lymphocytic Leukemia

Shots:

  • The P-III ELEVATE-TN trial involves assessing of Calquence (100 mg bid) as monothx and + obinutuzumab vs chlorambucil + obinutuzumab in 535 patients in ratio (1:1:1) with previously untreated CLL
  • The study resulted in meeting 1EPs & 2EPs with improvement in PFS as monothx & combination and was safe & well-tolerated when compared with the CT-based combination of chlorambucil and obinutuzumab
  • Calquence is a Bruton tyrosine kinase (BTK) inhibitor has received the US FDA’s accelerated approval in Oct 2017 for patients with 1L MCL in adults and is currently evaluated in multiple P-III trials in CLL including ASCEND, ELEVATE-TN, ELEVATE-RR (ACE-CL-006)

Click here to read full press release/ article | Ref: AstraZeneca | Image: Xtra Shot